Science Pool

Evotec-partner Jingxin receives approval for EVT201 in China

Evotec SE announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia treatment EVT201, also known as Dimdazenil in China. 

Read More

Twitter
LinkedIn
Email